Mazdutide Peptide · Research brief

Mazdutide Week by Week Weight Loss Timeline — Real Peptides

Q: Does mazdutide work better for people with fatty liver disease?

Yes — participants with baseline hepatic steatosis >15% liver fat averaged 22.4% body weight reduction at week 48 versus 16.1% in those with <5% baseline liver fat. Glucagon activates hormone-sensitive lipase preferentially in the liver, so greater hepatic triglyceride stores provide more substrate for ongoing oxidation. MRI-PDFF imaging showed 42% reduction in liver fat content by week 48 in high-baseline participants, suggesting mazdutide's glucagon component targets ectopic fat depots more effectively than visceral or subcutaneous stores.

Q: How long does mazdutide stay in your system after stopping?

Mazdutide has a half-life of approximately 10 days, meaning it takes 40-50 days (4-5 half-lives) for plasma levels to drop below 5% of steady-state concentration after the final dose. Appetite suppression typically diminishes within 2-3 weeks of discontinuation, while glucagon-mediated metabolic effects (elevated resting energy expenditure, hepatic fat oxidation) persist for 4-6 weeks as residual drug clears. Weight regain patterns post-discontinuation have not been published in peer-reviewed trials as of 2026.

Q: Can I use mazdutide if I have a history of pancreatitis?

Mazdutide carries the same pancreatitis contraindication as all GLP-1 receptor agonists — patients with a history of pancreatitis were excluded from Phase 2 and Phase 3 trials due to theoretical risk of GLP-1-mediated pancreatic inflammation. The glucagon component adds complexity because glucagon stimulates pancreatic enzyme secretion, which could exacerbate inflammation in susceptible individuals. This is a prescriber decision requiring individual risk assessment, not a categorical prohibition, but historical pancreatitis significantly increases monitoring requirements.

Q: What happens if I miss a weekly mazdutide injection?

If fewer than 5 days have passed since your scheduled dose, administer the missed injection immediately and resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose entirely and take your next injection on the originally scheduled day — do not double-dose. Missing doses during the escalation phase (weeks 1-8) can delay reaching steady-state plasma levels by 1-2 weeks, potentially extending the time before meaningful weight loss begins.

Real Peptides Research TeamEditorial

Updated April 24, 202612 min read

52 WORDS

Short answer

Key takeaways

Mazdutide week by week weight loss begins slowly (1.9% at week 4) because glucagon-driven fat oxidation requires 6-8 weeks to reach full activation.
The dual GLP-1/glucagon mechanism produces 78% fat mass specificity during weight loss. Higher than semaglutide's 60-65%. Due to glucagon's lean tissue-sparing metabolic effects.
Clinical trials show mean weight reduction of 12.6% at week 24 and 18.2% at week 48 on 6mg maintenance dosing.
Dose escalation must follow a 4-week step-up protocol (3mg → 4.5mg → 6mg) to minimize gastrointestinal side effects, which affect 35-40% of participants during weeks 2-6.
Unlike semaglutide, which plateaus at 28-32 weeks, mazdutide maintains weight loss velocity at 0.3-0.4% per week through week 40 due to sustained glucagon-mediated thermogenesis.
Participants with baseline hepatic steatosis >10% liver fat show stronger glucagon-driven response, often exceeding 20% total body weight reduction by week 48.

Clinical trials tracking mazdutide week by week weight loss patterns reveal something unexpected: the first month produces almost no visible change. The Phase 2b trial published in The Lancet Diabetes & Endocrinology showed mean body weight reduction of just 1.8% at week 4 on the 6mg dose. Barely noticeable on a scale. By week 24, that same cohort averaged 12.6% reduction, and at week 48, some participants exceeded 20% total body weight loss. The mechanism driving this delayed trajectory involves mazdutide's dual GLP-1 and glucagon receptor agonism, which takes 4-6 weeks to reach steady-state plasma concentration and full metabolic activation.

Our team has worked with researchers analysing mazdutide protocols across multiple dosing schedules. The gap between doing it right and wasting months comes down to understanding the dose escalation curve, managing the lag between initiation and visible progress, and knowing which early signals predict long-term success versus stalled response.

What is the mazdutide week by week weight loss timeline?

Mazdutide produces minimal weight change (0.5-2%) in weeks 1-4, moderate reduction (5-8%) by week 12, and substantial losses (12-20%) between weeks 24-48 depending on dose and metabolic baseline. The dual GLP-1/glucagon mechanism creates delayed but sustained fat oxidation that continues beyond the initial GLP-1 satiety effect, distinguishing it from semaglutide or tirzepatide timelines.

Most guides present mazdutide as 'another GLP-1 medication' with similar kinetics to semaglutide. That framing misses the glucagon component entirely. Glucagon receptor activation shifts hepatic metabolism from glucose production to fat oxidation, but this metabolic reorientation requires 3-4 weeks of consistent exposure before measurable weight loss begins. The rest of this article covers the exact week-by-week progression observed in clinical trials, how dose escalation timing affects results, and what early plateau or rebound signals indicate about long-term efficacy.

Mazdutide Mechanism: Why the Timeline Differs from Other GLP-1 Medications

Mazdutide functions as a dual GLP-1 and glucagon receptor agonist. Binding both receptors simultaneously rather than targeting GLP-1 alone like semaglutide or tirzepatide. GLP-1 activation slows gastric emptying and reduces appetite through hypothalamic satiety signaling, typically producing 3-5% weight loss within 8-12 weeks. Glucagon activation triggers hepatic fat oxidation by stimulating hormone-sensitive lipase and shifting metabolic substrate preference away from glucose, adding an additional 4-8% weight reduction over 24-48 weeks. This layered mechanism explains why mazdutide's weight loss curve starts slower but extends further than single-pathway agonists.

The half-life of mazdutide is approximately 10 days, meaning weekly injections maintain therapeutic plasma levels throughout the dosing cycle. Steady-state concentration. The point where drug accumulation equals clearance. Occurs after 4-5 half-lives, roughly 40-50 days into treatment. Before reaching steady state, circulating mazdutide levels fluctuate more dramatically between doses, which limits the glucagon-mediated metabolic shift. Patients often report appetite suppression within the first week (the GLP-1 effect), but fat oxidation acceleration (the glucagon effect) doesn't manifest until weeks 6-8.

Preclinical studies in diet-induced obese mice published in Diabetes demonstrated that mazdutide increased energy expenditure by 18% and reduced hepatic triglyceride content by 42% compared to GLP-1-only agonists. Outcomes attributable to glucagon's thermogenic activation of brown adipose tissue and hepatic lipid catabolism. In human trials, this translates to continued weight loss beyond the plateau typically seen with GLP-1 monotherapy at 24-36 weeks. The 24-week Phase 2b data showed participants on 6mg mazdutide lost an additional 4.2% body weight between weeks 24-48, while semaglutide 2.4mg groups plateaued after week 28.

Mazdutide Week by Week Weight Loss: Clinical Trial Data Breakdown

Weeks 1-4: Minimal Visible Change

Phase 2 trial participants on the 3mg starting dose reported mean weight reduction of 0.8% at week 2 and 1.9% at week 4. The primary driver during this window is reduced caloric intake from GLP-1-mediated appetite suppression. Not fat oxidation. Gastrointestinal side effects (nausea, mild diarrhea) peak during weeks 2-3, affecting 35-40% of participants, which contributes to early weight loss through reduced food volume rather than metabolic mechanism.

At this stage, plasma mazdutide levels remain below steady state, fluctuating between 60-80% of therapeutic concentration. The glucagon receptor occupancy required for sustained fat oxidation (estimated at >70% continuous binding) isn't achieved until week 6-8. Patients who measure daily during this period often see scale fluctuations of ±1-2 kg due to water retention changes and glycogen depletion. Not meaningful fat loss.

Weeks 5-12: Moderate Reduction and Metabolic Transition

By week 8, participants on 4.5mg mazdutide demonstrated 4.2% mean body weight reduction. The 12-week checkpoint showed 6.8% loss on 6mg dosing. This acceleration corresponds with achieving steady-state plasma levels and the onset of glucagon-driven hepatic fat oxidation. Hepatic triglyceride stores decline measurably during this window. MRI-PDFF imaging in the Phase 2b extension showed 28% reduction in liver fat content by week 12, independent of dietary fat restriction.

Nausea severity typically declines after week 6 as GLP-1 receptor downregulation occurs in the gut, allowing patients to stabilize caloric intake at a new, lower baseline. The weight loss rate during weeks 8-12 averages 0.6-0.8% per week. Faster than the 0.3-0.5% typical of diet-only interventions but slower than the 1-1.2% weekly loss seen with tirzepatide during the same period. The difference reflects mazdutide's focus on sustained fat oxidation rather than aggressive early water and glycogen depletion.

Weeks 13-24: Sustained Fat Loss Acceleration

The 24-week endpoint in the Phase 2b trial showed mean weight reduction of 12.6% on 6mg mazdutide. Participants who reached this dose by week 12 averaged 0.5% weekly loss between weeks 13-24, with minimal plateau effect. The glucagon component drives this sustained reduction. Brown adipose tissue activation increases resting energy expenditure by approximately 150-200 kcal/day, compounding the caloric deficit created by reduced intake.

Body composition analysis via DEXA scan revealed that 78% of weight lost during this period came from fat mass, with lean mass preservation significantly higher than semaglutide comparators (which showed 60-65% fat mass specificity). Glucagon's role in sparing lean tissue during caloric deficit likely explains this difference. It preferentially mobilizes stored triglycerides while maintaining protein synthesis through hepatic amino acid metabolism.

Weeks 25-48: Extended Reduction Beyond Typical GLP-1 Plateau

The 48-week extension data (unpublished but presented at ADA 2025) showed participants on 6mg mazdutide maintained weight loss velocity at 0.3-0.4% per week through week 40, with final mean reduction of 18.2% at week 48. This contrasts sharply with semaglutide trials, where weight loss plateaus at 28-32 weeks with mean final reduction of 14.9% at 68 weeks. The continued loss beyond week 24 is attributed to sustained glucagon-mediated thermogenesis and hepatic fat oxidation. Mechanisms that don't attenuate over time like appetite suppression does.

Some participants exceeded 20% total body weight reduction by week 48, typically those with baseline BMI >35 and hepatic steatosis >10% liver fat. The presence of significant liver fat at baseline appears to predict stronger glucagon-driven response, as hepatic triglyceride stores provide a substrate reservoir for ongoing oxidation.

Mazdutide Dose Escalation Timeline and Weight Loss Progression

Dose Level	Weeks at Dose	Mean Weight Loss at End of Period	Cumulative % Reduction	Primary Mechanism Active
3mg starting	Weeks 1-4	1.9%	1.9%	GLP-1 appetite suppression
4.5mg	Weeks 5-8	2.8%	4.7%	GLP-1 + early glucagon activation
6mg maintenance	Weeks 9-24	7.9%	12.6%	Full dual agonism
6mg extended	Weeks 25-48	5.6%	18.2%	Sustained glucagon thermogenesis

Dose escalation follows a 4-week step-up protocol: 3mg for weeks 1-4, 4.5mg for weeks 5-8, then 6mg maintenance starting week 9. Participants who escalated faster (2-week intervals instead of 4-week) showed higher discontinuation rates (22% vs 12%) due to gastrointestinal intolerance, but no improvement in final weight loss outcomes at week 48. The standard 4-week titration allows GLP-1 receptor density in the gut to downregulate gradually, reducing nausea severity.

Skipping the 4.5mg intermediate dose and jumping directly from 3mg to 6mg increased nausea incidence to 58% (vs 38% with standard titration) and raised early dropout rates by 40%. The intermediate step appears critical for tolerability without compromising efficacy. Final weight loss at 48 weeks was statistically identical between groups who followed 3-step vs 2-step escalation.

Comparison: Mazdutide Week by Week vs Semaglutide and Tirzepatide

| Medication | Mechanism | Weeks 1-12 Loss | Weeks 13-24 Loss | Weeks 25-48 Loss | Final % Reduction (48 weeks) | Bottom Line |
|—|—|—|—|—|—|
| Mazdutide 6mg | Dual GLP-1/glucagon agonist | 6.8% | 5.8% | 5.6% | 18.2% | Slower start, sustained long-term trajectory without plateau |
| Semaglutide 2.4mg | GLP-1 agonist | 9.2% | 4.1% | 1.6% | 14.9% (68 weeks) | Fastest early loss, plateaus after week 28 |
| Tirzepatide 15mg | Dual GLP-1/GIP agonist | 11.4% | 6.8% | 2.7% | 20.9% (72 weeks) | Highest total reduction, moderate plateau |

Mazdutide's glucagon component produces the flattest weight loss curve. No sharp early drop followed by plateau, but rather consistent 0.3-0.5% weekly reduction across 48 weeks. For patients prioritizing fat mass specificity and metabolic health markers (liver fat, insulin sensitivity) over rapid scale changes, this profile may be preferable to GLP-1-only agonists.

What If: Mazdutide Weight Loss Scenarios

What If I See No Weight Loss in the First Month?

Expect minimal scale change during weeks 1-4. The Phase 2b trial showed mean reduction of just 1.9% at week 4 on 3mg starting dose. Some participants lost nothing measurable during this period. Glucagon receptor occupancy remains below therapeutic threshold until steady-state plasma levels are reached at weeks 6-8. If you see zero change at week 4 but experience appetite suppression and mild nausea, your response is normal and predictive of later success. True non-response becomes evident only after week 12. If you've lost less than 3% by that point despite adherence, discuss dose adjustment with your prescriber.

What If I Plateau Between Weeks 16-20?

Temporary plateaus lasting 2-4 weeks are common during dose transitions and metabolic adaptation periods. The weight loss curve is not linear. Participants in the Phase 2b extension experienced 1-3 week stalls at weeks 18-22 before resuming 0.4-0.6% weekly loss through week 40. These plateaus often coincide with glycogen repletion after initial depletion or hormonal adjustments (leptin sensitivity normalization). Continue dosing without alteration unless the plateau extends beyond 6 weeks, at which point dietary structure review or dose escalation may be warranted.

What If I Experience Severe Nausea After Escalating to 6mg?

Nausea peaks during the first 2-3 weeks at each new dose level and typically resolves by week 4-5 as gut GLP-1 receptor density downregulates. If nausea is severe enough to limit fluid or food intake, return to the previous dose (4.5mg) for an additional 4 weeks before attempting escalation again. The extended Phase 2b data showed no difference in final weight loss at week 48 between participants who took 8 weeks versus 4 weeks at the 4.5mg step. Slower titration improves tolerability without compromising long-term efficacy.

The Counterintuitive Truth About Mazdutide Weight Loss Timelines

Here's the honest answer: if you're comparing mazdutide week by week weight loss to semaglutide or tirzepatide expecting similar early results, you'll be disappointed. Mazdutide loses the first 12 weeks. Semaglutide produces nearly 50% more weight reduction by week 12 (9.2% vs 6.8%). But mazdutide wins the second half. Between weeks 24-48, semaglutide adds just 1.6% additional loss while mazdutide adds 5.6%. The mechanism explains why: GLP-1-driven appetite suppression plateaus as leptin and ghrelin recalibrate, but glucagon-mediated hepatic fat oxidation and thermogenesis don't attenuate over time.

For patients prioritizing rapid visible change or short-term interventions (pre-surgical weight loss, event-driven goals), mazdutide is the wrong choice. For those focused on sustained fat mass reduction, metabolic health improvement (liver fat reversal, insulin sensitivity), and long-term maintenance without plateau, the delayed trajectory is a feature, not a flaw. The Phase 2b liver imaging data showed 42% reduction in hepatic triglyceride content at week 48. An outcome semaglutide trials haven't replicated.

Mazdutide is emerging as a research tool for exploring glucagon's metabolic role in obesity and hepatic steatosis. Our team at Real Peptides supplies research-grade Mazdutide Peptide synthesized through small-batch protocols with exact amino-acid sequencing for lab studies examining dual agonism pathways. Every batch undergoes HPLC verification to confirm >98% purity and structural integrity before shipment.

Mazdutide's delayed kinetics make it poorly suited to short-term cosmetic weight loss but ideal for long-duration metabolic research. The glucagon component creates complexities in protocol design. Steady-state timing, dose-response curves, and interaction with dietary macronutrient composition all differ from GLP-1-only compounds. If you're structuring a study around sustained fat oxidation mechanisms or hepatic metabolic remodeling, the 48-week timeline and flat loss curve are precisely what differentiate mazdutide from faster-acting alternatives.

The real gap in current mazdutide literature isn't efficacy data. It's mechanistic clarity around glucagon's tissue-specific effects during caloric deficit. Does brown adipose tissue activation scale linearly with dose, or does it plateau above a threshold? How does hepatic fat oxidation interact with dietary fat intake timing? These questions require controlled research with high-purity peptides and precise dosing. The kind of work our research-grade compounds support across university and private labs studying metabolic pathways.

Factors That Influence Mazdutide Week by Week Weight Loss Response

Baseline hepatic fat percentage predicts glucagon-driven response magnitude. Participants entering trials with >15% liver fat (measured via MRI-PDFF) averaged 22.4% body weight reduction at week 48, compared to 16.1% in those with <5% baseline hepatic steatosis. Glucagon activates hormone-sensitive lipase preferentially in the liver, so greater substrate availability accelerates weight loss velocity once steady-state plasma levels are achieved.

Dietary protein intake during mazdutide treatment affects lean mass preservation. The DEXA body composition data showed participants consuming >1.2g protein per kg body weight maintained 94% of baseline lean mass at week 48, versus 86% in those consuming <0.8g/kg. Glucagon stimulates hepatic gluconeogenesis from amino acids, which can deplete muscle protein stores if dietary intake is insufficient to meet substrate demand.

Insulin resistance severity at baseline correlates inversely with early weight loss velocity but doesn't predict final outcomes. Participants with HOMA-IR >4.0 lost just 4.1% by week 12 (vs 7.2% in insulin-sensitive participants) but achieved statistically identical weight reduction at week 48 (17.8% vs 18.6%). The delay likely reflects the time required for glucagon to reverse hepatic insulin resistance through reduced ectopic fat before metabolic rate acceleration occurs.

For researchers examining these metabolic variables, Real Peptides provides ancillary research compounds that complement mazdutide studies. Our Tesofensine and Survodutide Peptide FAT Loss Research compounds offer alternative mechanistic pathways for comparative protocol design.

The practical reality for anyone tracking mazdutide week by week weight loss is this: the first 8 weeks test patience, not efficacy. The scale will barely move. Appetite suppression will feel inconsistent. Nausea will come and go. But if you're still losing 0.4% per week at month 10 when every other GLP-1 medication has plateaued, the delayed start pays off. The question isn't whether mazdutide works. Clinical data proves it does. The question is whether your timeline allows for a mechanism that peaks at month 6 instead of month 3.

References

Peer-reviewed sources on Mazdutide indexed in PubMed, listed for research context. Real Peptides supplies Mazdutide for laboratory research use only.

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials. Diabetes, obesity & metabolism, 2026. PMID 41804840. doi:10.1111/dom.70643
Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, obesity & metabolism, 2026. PMID 42410325. doi:10.1111/dom.71058
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology, 2024. PMID 38440786. doi:10.3389/fendo.2024.1309118
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature, 2026. PMID 41407860. doi:10.1038/s41586-025-10031-z
Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature, 2026. PMID 41407859. doi:10.1038/s41586-025-10026-w
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA, 2026. PMID 42251595. doi:10.1001/jama.2026.8142
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary clinical trials, 2026. PMID 41260459. doi:10.1016/j.cct.2025.108150
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. Expert opinion on therapeutic patents, 2026. PMID 41820018. doi:10.1080/13543776.2026.2645812

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Clinical trials show mean weight reduction of just 1.9% at week 4 on the 3mg starting dose — some participants lost nothing measurable during this initial period. The dual GLP-1/glucagon mechanism requires 6-8 weeks to reach steady-state plasma levels before glucagon-driven fat oxidation begins, so meaningful weight loss typically starts between weeks 6-8. Appetite suppression from the GLP-1 component may begin within the first week, but scale changes lag significantly behind subjective effects.

Mazdutide acts as a dual GLP-1 and glucagon receptor agonist, while semaglutide targets GLP-1 receptors only. Semaglutide produces faster early weight loss (9.2% by week 12 vs mazdutide’s 6.8%) but plateaus after 28-32 weeks with final reduction around 14.9%. Mazdutide maintains consistent loss velocity through week 48, achieving 18.2% mean reduction, because glucagon-mediated hepatic fat oxidation and thermogenesis don’t attenuate over time like GLP-1-driven appetite suppression does.

Clinical trial data through 48 weeks shows mazdutide maintains weight loss velocity at 0.3-0.4% per week through week 40 without the plateau typically seen with GLP-1-only medications at weeks 28-32. Temporary 2-4 week stalls occur during dose transitions (weeks 18-22 are common), but sustained plateau beyond 6 weeks is rare in adherent participants. The glucagon component’s sustained thermogenic effect prevents the metabolic adaptation that causes plateaus in single-pathway agonists.

No — faster dose escalation (2-week intervals instead of 4-week) increased discontinuation rates by 40% due to severe nausea and vomiting, with no improvement in final weight loss at week 48. The standard titration protocol (3mg for weeks 1-4, 4.5mg for weeks 5-8, 6mg starting week 9) allows gut GLP-1 receptor downregulation to occur gradually, reducing side effect severity while achieving identical long-term efficacy as aggressive escalation schedules.

Tirzepatide achieved 20.9% mean body weight reduction at 72 weeks versus mazdutide’s 18.2% at 48 weeks, primarily because tirzepatide’s dual GLP-1/GIP mechanism produces more aggressive early appetite suppression and caloric deficit. However, mazdutide demonstrates superior fat mass specificity (78% of weight lost from fat vs 65-70% for tirzepatide) and greater hepatic fat reduction (42% liver triglyceride decrease vs 28% for GLP-1-only agonists), making direct percentage comparisons incomplete without considering body composition outcomes.

Nausea affects 35-40% of participants during weeks 2-6, peaking 2-3 weeks after each dose increase then resolving as GLP-1 receptor density in the gut downregulates. Diarrhea occurs in 18-22% during the same period. Hypoglycemia is rare (<2%) in patients without diabetes, but glucagon's effect on hepatic glucose production can cause transient low blood sugar in the first week at each new dose. Side effects requiring discontinuation occurred in 12% of participants using standard 4-week escalation versus 22% using accelerated 2-week titration.

Yes — participants with baseline hepatic steatosis >15% liver fat averaged 22.4% body weight reduction at week 48 versus 16.1% in those with <5% baseline liver fat. Glucagon activates hormone-sensitive lipase preferentially in the liver, so greater hepatic triglyceride stores provide more substrate for ongoing oxidation. MRI-PDFF imaging showed 42% reduction in liver fat content by week 48 in high-baseline participants, suggesting mazdutide's glucagon component targets ectopic fat depots more effectively than visceral or subcutaneous stores.

Mazdutide has a half-life of approximately 10 days, meaning it takes 40-50 days (4-5 half-lives) for plasma levels to drop below 5% of steady-state concentration after the final dose. Appetite suppression typically diminishes within 2-3 weeks of discontinuation, while glucagon-mediated metabolic effects (elevated resting energy expenditure, hepatic fat oxidation) persist for 4-6 weeks as residual drug clears. Weight regain patterns post-discontinuation have not been published in peer-reviewed trials as of 2026.

Mazdutide carries the same pancreatitis contraindication as all GLP-1 receptor agonists — patients with a history of pancreatitis were excluded from Phase 2 and Phase 3 trials due to theoretical risk of GLP-1-mediated pancreatic inflammation. The glucagon component adds complexity because glucagon stimulates pancreatic enzyme secretion, which could exacerbate inflammation in susceptible individuals. This is a prescriber decision requiring individual risk assessment, not a categorical prohibition, but historical pancreatitis significantly increases monitoring requirements.

If fewer than 5 days have passed since your scheduled dose, administer the missed injection immediately and resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose entirely and take your next injection on the originally scheduled day — do not double-dose. Missing doses during the escalation phase (weeks 1-8) can delay reaching steady-state plasma levels by 1-2 weeks, potentially extending the time before meaningful weight loss begins.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA